Key Takeaways Bayer's finerenone met the primary endpoint in the phase III FIND-CKD study in non-diabetic CKD patients.Finerenone slowed kidney function decline vs placebo, reinforcing benefits beyond diabetic CKD.Bayer plans regulatory filings to expand Kerendia's indication following strong late-stage results.Bayer (BAYRY) announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone in expanding its use to patients with non-diabetic chronic kidney disea ...